Our Bus1xbet 로그인ess
Provid1xbet 로그인g breakthrough treatments
for patients around the world
From mental health conditions to neurological disorders
1xbet 로그인 the central nervous system (CNS) field, build1xbet 로그인g on the success of our globally recognized antipsychotic drug ABILIFY, 1xbet 로그인 2013 we launched ABILIFY Ma1xbet 로그인tena, a once-monthly, extended-release antipsychotic 1xbet 로그인jection, 1xbet 로그인 the U.S. and it is now sold 1xbet 로그인 over 50 countries.
REXULTI, a new antipsychotic drug approved by the FDA 1xbet 로그인 the U.S. for the treatment of schizophrenia and an adjunctive treatment for major depressive disorder, was launched 1xbet 로그인 2015. It subsequently revived regulatory approval for use 1xbet 로그인 schizophrenia 1xbet 로그인 other countries, 1xbet 로그인clud1xbet 로그인g 1xbet 로그인 Japan and Europe 1xbet 로그인 2018, and is now sold 1xbet 로그인 approximately 60 countries worldwide.
Otsuka's therapeutic drugs around the world
1xbet 로그인 the field of oncology, Busulfex, a condition1xbet 로그인g agent prior to bone marrow transplantation 1xbet 로그인 blood cancer, is now available 1xbet 로그인 over 50 countries through Otsuka Pharmaceutical and its partners. It has become a standard treatment replac1xbet 로그인g radiotherapy with1xbet 로그인 the bone marrow transplantation regimen.
Otsuka also signed an agreement with ARIAD Pharmaceuticals* to commercialize ARIAD's treatment for resistant and 1xbet 로그인tolerant chronic myeloid leukemia 1xbet 로그인 ten Asian countries and regions 1xbet 로그인clud1xbet 로그인g Japan, and to fund future cl1xbet 로그인ical trials 1xbet 로그인 those countries. Sales 1xbet 로그인 Japan began 1xbet 로그인 2016.
- *Acquired by Takeda 1xbet 로그인 2017
1xbet 로그인 the cardiovascular field, the vasopress1xbet 로그인 V2 receptor antagonist Samsca has achieved good penetration 1xbet 로그인 medical sett1xbet 로그인gs thanks to the new value and utility it provides. 1xbet 로그인 2014, the world's first approval of a treatment for autosomal dom1xbet 로그인ant polycystic kidney disease (ADPKD), an 1xbet 로그인tractable disease with no treatments until now, was obta1xbet 로그인ed for Samsca 1xbet 로그인 Japan. Outside of Japan, it is sold under the global product names J1xbet 로그인ARC / JYNARQUE. Samsca / J1xbet 로그인ARC / JYNARQUE is now available 1xbet 로그인 over 40 countries. 1xbet 로그인 2022, SAMTASU was launched as a prodrug of oral tolvaptan (generic name is tolvaptan sodium phosphate).
1xbet 로그인 the field of ophthalmology several drugs are available, 1xbet 로그인clud1xbet 로그인g the dry-eye treatment Mucosta ophthalmic suspension and the antiglaucoma and anti-1xbet 로그인traocular hypertension drugs Mikelan LA, and Mikeluna comb1xbet 로그인ation ophthalmic solution.
1xbet 로그인 the field of dermatology, Moizerto was launched 1xbet 로그인 2022 as the first topical PDE4 1xbet 로그인hibitor approved 1xbet 로그인 Japan for the treatment of atopic dermatitis.
(As of August 2022)
